BR0113188A - Application of perfluoroalkyl-containing metal complexes as contrast agents in magnetic resonance imaging for the identification of plaques, tumors and necroses - Google Patents

Application of perfluoroalkyl-containing metal complexes as contrast agents in magnetic resonance imaging for the identification of plaques, tumors and necroses

Info

Publication number
BR0113188A
BR0113188A BR0113188-5A BR0113188A BR0113188A BR 0113188 A BR0113188 A BR 0113188A BR 0113188 A BR0113188 A BR 0113188A BR 0113188 A BR0113188 A BR 0113188A
Authority
BR
Brazil
Prior art keywords
perfluoroalkyl
magnetic resonance
application
identification
necroses
Prior art date
Application number
BR0113188-5A
Other languages
Portuguese (pt)
Inventor
Johannes Platzek
Peter Mareski
Ulrich Niedballa
Bernd Raduechel
Hanns-Joachim Weinmann
Bernd Misselwitz
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10040380A external-priority patent/DE10040380B4/en
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0113188A publication Critical patent/BR0113188A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

"APLICAçãO DE COMPLEXOS DE METAL CONTENDO PERFLUOROALQUILA COMO AGENTES DE CONTRASTE NA IMAGEM DE RESSONâNCIA MAGNéTICA PARA A IDENTIFICAçãO DE PLACAS, TUMORES E NECROSES". A invenção refere-se à aplicação de complexos de metal contendo perfluoroalquila, que apresentam uma concentração de formação de micélio crítica <10^ -3^ mol/l, u diâmetro de micélio hidrodinâmico (2 Rh)> 1 nm e uma "relaxivity" de prótons no plasma (R^ 1^) > 10 l/mmoles.s, como agentes de contraste na imagem de ressonância magnética, tanto para a identificação de placas, gânglios linfáticos, tecido infartado e necrosado como também para a identificação independente de tecido necrosado e tecido de tumor."APPLICATION OF METAL COMPLEX CONTAINING PERFluoroalkyl AS AGENTS OF CONTRAST IN MAGNETIC RESONANCE IMAGE FOR IDENTIFYING PLATES, TUMORS AND NECROSES". The invention relates to the application of perfluoroalkyl-containing metal complexes which have a critical mycelium formation concentration of <10 ^ -3 ^ mol / l, a hydrodynamic mycelium (2 Rh) diameter> 1 nm and a "relaxivity". of plasma protons (R ^ 1 ^)> 10 l / mmoles.s, as contrast agents in magnetic resonance imaging, both for the identification of plaques, lymph nodes, infarcted and necrotic tissue as well as for the independent identification of tissue necrotic and tumor tissue.

BR0113188-5A 2000-08-11 2001-07-23 Application of perfluoroalkyl-containing metal complexes as contrast agents in magnetic resonance imaging for the identification of plaques, tumors and necroses BR0113188A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10040380A DE10040380B4 (en) 2000-08-11 2000-08-11 MRI contrast agent for visualization of plaque, lymph nodes, infarcted and necrotic tissue or both necrosis and tumors, comprising perfluoroalkylated metal complex having specific micelle forming properties
PCT/EP2001/008498 WO2002013874A2 (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses

Publications (1)

Publication Number Publication Date
BR0113188A true BR0113188A (en) 2003-06-24

Family

ID=7652860

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113188-5A BR0113188A (en) 2000-08-11 2001-07-23 Application of perfluoroalkyl-containing metal complexes as contrast agents in magnetic resonance imaging for the identification of plaques, tumors and necroses

Country Status (26)

Country Link
EP (1) EP1307236A2 (en)
JP (1) JP2004506025A (en)
KR (1) KR20030022387A (en)
CN (1) CN1469757A (en)
AR (1) AR034139A1 (en)
AU (2) AU7754901A (en)
BG (1) BG107542A (en)
BR (1) BR0113188A (en)
CA (1) CA2419223A1 (en)
CZ (1) CZ2003392A3 (en)
DE (1) DE10066210B4 (en)
EE (1) EE200300061A (en)
HR (1) HRP20030173A2 (en)
HU (1) HUP0300736A3 (en)
IL (1) IL154385A0 (en)
MX (1) MXPA03001287A (en)
NO (1) NO20030604L (en)
NZ (1) NZ523932A (en)
PL (1) PL365596A1 (en)
RU (1) RU2290206C2 (en)
SK (1) SK1572003A3 (en)
TW (1) TWI296931B (en)
UA (1) UA82642C2 (en)
WO (1) WO2002013874A2 (en)
YU (1) YU10603A (en)
ZA (1) ZA200301949B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
DE10231799B4 (en) * 2002-07-10 2006-10-05 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast agents in MR imaging for the presentation of intravascular thrombi
DE102005008309A1 (en) * 2005-02-17 2006-08-24 Schering Ag Pharmaceutical agents containing fluoroalkyl-containing metal complexes and epothilones
DE102006021495A1 (en) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Use of metal chelate containing perfluorinated alkyl-residue, chelator-residue and metal ion equivalent to the atomic number, for the production of diagnostic agent for representation of amyloid-containing plaques
US7887835B2 (en) * 2006-09-19 2011-02-15 Fujifilm Corporation Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound
DE102006049821A1 (en) * 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft New, well tolerated metal chelates, for use as radiodiagnostic, radiotherapeutic or NMR and X-ray diagnostic agents, contain chelator and perfluorinated polyethylene glycol residues
DE102007015598A1 (en) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Use of fluorochemical compounds for diagnostic purposes using imaging techniques
JP2011190183A (en) * 2010-03-11 2011-09-29 Noguchi Institute Fluorous sugar-bonded crown ether derivative
US9976072B2 (en) 2014-03-26 2018-05-22 Chevron U.S.A. Inc. Multicarboxylate compositions and method of making the same
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US11104639B2 (en) 2016-09-14 2021-08-31 Daikin Industries, Ltd. Branched fluorine-containing compound
CA3044877A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
SG11202104657RA (en) 2018-11-23 2021-06-29 Bayer Ag Formulation of contrast media and process of preparation thereof
CN109867635A (en) * 2019-02-14 2019-06-11 华东师范大学 A kind of T1 type micella magnetic resonance imaging contrast and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19603033A1 (en) * 1996-01-19 1997-07-24 Schering Ag Perfluoroalkyl-containing metal complexes, processes for their preparation and their use in NMR diagnostics
JPH10112939A (en) * 1996-10-07 1998-04-28 Nec Corp Power switching circuit
DE19729013A1 (en) * 1997-07-03 1999-02-04 Schering Ag Oligomeric, perfluoroalkyl-containing compounds, processes for their preparation and their use in NMR diagnostics
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis

Also Published As

Publication number Publication date
KR20030022387A (en) 2003-03-15
WO2002013874A2 (en) 2002-02-21
JP2004506025A (en) 2004-02-26
YU10603A (en) 2006-05-25
AR034139A1 (en) 2004-02-04
EE200300061A (en) 2004-12-15
BG107542A (en) 2003-09-30
ZA200301949B (en) 2004-12-14
EP1307236A2 (en) 2003-05-07
MXPA03001287A (en) 2003-10-06
RU2290206C2 (en) 2006-12-27
NZ523932A (en) 2007-07-27
CN1469757A (en) 2004-01-21
DE10066210B4 (en) 2008-02-28
SK1572003A3 (en) 2003-10-07
CZ2003392A3 (en) 2003-09-17
IL154385A0 (en) 2003-09-17
NO20030604L (en) 2003-04-11
HUP0300736A2 (en) 2003-09-29
PL365596A1 (en) 2005-01-10
HRP20030173A2 (en) 2005-04-30
AU7754901A (en) 2002-02-25
CA2419223A1 (en) 2003-02-11
WO2002013874A8 (en) 2002-06-13
UA82642C2 (en) 2008-05-12
NO20030604D0 (en) 2003-02-07
AU2001277549B2 (en) 2007-02-08
HUP0300736A3 (en) 2010-01-28
TWI296931B (en) 2008-05-21

Similar Documents

Publication Publication Date Title
BR0113188A (en) Application of perfluoroalkyl-containing metal complexes as contrast agents in magnetic resonance imaging for the identification of plaques, tumors and necroses
Ojiri et al. Potentially distinctive features of sinonasal inverted papilloma on MR imaging
Kobayashi et al. Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals
Toth et al. Relaxivity of gadolinium (III) complexes: theory and mechanism
Gunasekera et al. Imaging applications of nanotechnology in cancer
Shin et al. Targeted nanoparticles in imaging: paving the way for personalized medicine in the battle against cancer
DK0907379T3 (en) Bioactivated diagnostic imaging contrast agent
Vila et al. Discrimination of benign and neoplastic mucosa with a high-resolution microendoscope (HRME) in head and neck cancer
Yang et al. Biodegradable Nanoprobe for NIR‐II Fluorescence Image‐Guided Surgery and Enhanced Breast Cancer Radiotherapy Efficacy
NO983060D0 (en) Imaging agents
Han et al. Targeted contrast agent specific to an oncoprotein in tumor microenvironment with the potential for detection and risk stratification of prostate cancer with MRI
US20100215581A1 (en) Contrast agents for detecting prostate cancer
NO20050679L (en) Use of metal complexes containing perfluoroalkyl as contrast agents in magnetic resonance imaging to exhibit intravascular thrombi
KR20170029430A (en) Library of ph responsive polymers and nanoprobes thereof
Temma et al. Radiolabelled probes for imaging of atherosclerotic plaques
McCann et al. Molecular imaging of tumor invasion and metastases: the role of MRI
Yang et al. Multifunctional upconversion nanoparticles for targeted dual-modal imaging in rat glioma xenograft
CN102802672A (en) Imaging of myelin basic protein
ATE309254T1 (en) TISSUE-SPECIFIC FLUORESCENT CHELATES
Hamon et al. Design of Bifunctional Pyclen-Based Lanthanide Luminescent Bioprobes for Targeted Two-Photon Imaging
Nakamura et al. Mesoscopic multimodal imaging provides new insight to tumor tissue evaluation: An example of macrophage imaging of hepatic tumor using organosilica nanoparticles
Borisova et al. Unique features of brain metastases-targeted AGuIX nanoparticles vs their constituents: A focus on glutamate-/GABA-ergic neurotransmission in cortex nerve terminals
ITMI20011706A0 (en) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS, USABLE FOR COMBINED DIAGNOSTIC INVESTIGATION THROUGH X-RAYS AND MAGNETIC RESONANCE
Bhosle et al. Membrane oxidative damage and apoptosis in cervical carcinoma cells of patients after radiation therapy
Dentamaro et al. Chemical and in vitro characterizations of a promising bimodal AGuIX probe able to target apoptotic cells for applications in MRI and optical imaging

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A , 9A E 10 ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.